Bisphosphonates, specifically Zometa, is commonly used in the treatment of men with advanced prostate cancer. Zometa is used to treat and protect bones from developing fractures. Bisphosphonates are potent inhibitors of bone resorption. Additionally, in vitro studies show that zolendronic acid also inhibits prostate cancer cell growth by activating apoptosis (A form of cell death [...]
The Washington Post has written an article about the funding controversy surrounding the Department of Defense (DOD) Medical Research Programs. I urge everyone to go to the web site and add your comments. Members of congress do read the Washington Post daily. Please go to: The Washington Post It would be a good idea if [...]
Researchers at the Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy performed a randomized phase II study which compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the standard of care D/prednisone (P) in men with advanced castrate-resistant prostate cancer (CRPC). […]
Tomorrow, Wednesday- March 2, I will be joining Dr. Daniel Petrylak for a number of radio interviews about prostate cancer. Dr. Petrylak is a world renowned prostate cancer researcher and clinician. He was the principal investigator in for the development of Taxotere (docetaxel). I anticipate that we will cover a number of different prostate cancer [...]
Researchers wanted to determine if concurrent the development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation) is associated with treatment regret among men with PSA recurrence following failed primary therapy for prostate cancer. The researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, [...]